Progenics Pharmaceuticals Getting Very Oversold (PGNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Monday, shares of Progenics Pharmaceuticals, Inc. ( PGNX) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $4.04 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 57.6. A bullish investor could look at PGNX's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of PGNX shares:

START SLIDESHOW:
Find out what 9 other oversold stocks you need to know about »

Progenics Pharmaceuticals, Inc. 1 Year Performance Chart

Looking at the chart above, PGNX's low point in its 52 week range is $1.41 per share, with $6.47 as the 52 week high point — that compares with a last trade of $4.15.


Earn a FREE $100 Membership to ValueForum, Just By Telling Us About Your Favorite Stock! (Offer ends 11/10/2013)
null

If you liked this article you might like

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

Reversal Offers Chance in 2 Small Biotechs

Reversal Offers Chance in 2 Small Biotechs

3 Tiny Explosive Biotech Stocks for 2018

3 Tiny Explosive Biotech Stocks for 2018

4 Small-Caps on My Earnings Watch List

4 Small-Caps on My Earnings Watch List